These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aspartame as a co-former in co-amorphous systems. Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253 [TBL] [Abstract][Full Text] [Related]
3. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers. Wu W; Grohganz H; Rades T; Löbmann K Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568 [TBL] [Abstract][Full Text] [Related]
4. Co-former selection for co-amorphous drug-amino acid formulations. Kasten G; Löbmann K; Grohganz H; Rades T Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980 [TBL] [Abstract][Full Text] [Related]
5. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability. Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766 [TBL] [Abstract][Full Text] [Related]
6. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574 [TBL] [Abstract][Full Text] [Related]
7. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization. Ruponen M; Visti M; Ojarinta R; Laitinen R Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814 [TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan. Huang Y; Zhang Q; Wang JR; Lin KL; Mei X Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301 [TBL] [Abstract][Full Text] [Related]
9. Development of a screening method for co-amorphous formulations of drugs and amino acids. Kasten G; Grohganz H; Rades T; Löbmann K Eur J Pharm Sci; 2016 Dec; 95():28-35. PubMed ID: 27531419 [TBL] [Abstract][Full Text] [Related]
14. The use of molecular descriptors in the development of co-amorphous formulations. Meng-Lund H; Kasten G; Jensen KT; Poso A; Pantsar T; Rades T; Rantanen J; Grohganz H Eur J Pharm Sci; 2018 Jul; 119():31-38. PubMed ID: 29649569 [TBL] [Abstract][Full Text] [Related]
15. Poly (amino acid)s as new co-formers in amorphous solid dispersion. Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970 [TBL] [Abstract][Full Text] [Related]
16. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems. Wu W; Löbmann K; Rades T; Grohganz H Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703 [TBL] [Abstract][Full Text] [Related]
17. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems. Wu W; Wang Y; Löbmann K; Grohganz H; Rades T Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075 [TBL] [Abstract][Full Text] [Related]
18. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior. Fael H; Demirel AL Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965 [TBL] [Abstract][Full Text] [Related]
19. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine. Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246 [TBL] [Abstract][Full Text] [Related]
20. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity. Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]